ARPA-H Just Bet $144 Million That Aging Itself Is a Treatable Condition

For decades, the federal government funded diseases. Cancer. Alzheimer's. Heart failure. Diabetes. Each condition got its own institute, its own study sections, its own budget line. The underlying biological process that makes all of them more likely — aging — got almost nothing.

ARPA-H just changed the math. The Advanced Research Projects Agency for Health announced up to $144 million over five years for its PROactive Solutions for Prolonging Resilience program, or PROSPR, awarding contracts to seven research teams to run clinical trials targeting biological aging directly. Not cancer. Not dementia. Aging itself — the cellular deterioration, chronic inflammation, and metabolic decline that precede and enable every major age-related disease.

This is the largest single federal commitment to healthspan extension in American history, and the structure is designed to produce results on a timeline that traditional NIH-funded aging research cannot match.

Why ARPA-H, Not NIH

The distinction matters. NIH funds research through grants — peer-reviewed proposals that give investigators broad latitude to pursue questions over multi-year timelines. ARPA-H funds programs through contracts — milestone-based agreements where teams must demonstrate measurable progress at defined intervals or lose their funding.

That structural difference shapes everything about PROSPR. The program is not asking whether aging can be slowed. It is asking which interventions slow aging measurably in human clinical trials within three years, using biomarkers validated against longitudinal health data rather than waiting for disease endpoints that take decades to manifest.

The logic is deceptively simple. Traditional clinical trials for age-related conditions require enrolling elderly patients, administering an intervention, and waiting years or decades to see whether they develop fewer diseases. PROSPR compresses that timeline by identifying early biomarkers — molecular, physiological, and functional markers that change before disease onset — and using them as surrogate endpoints in trials lasting 1 to 3 years.

If the biomarkers prove predictive and the interventions move them in the right direction, PROSPR teams will have generated human efficacy data for aging interventions faster than any previous program. If the biomarkers fail to correlate with long-term outcomes, ARPA-H will know that too — and will redirect funding accordingly, because that is how milestone-based contracts work.

The Seven Teams and What They Are Testing

PROSPR's awardee portfolio spans four universities, two biotech companies, and one private research organization. The interventions range from repurposed FDA-approved drugs to novel compounds targeting mechanisms that the aging research community has debated for a decade.

UT Health San Antonio received one of the program's largest awards for a Phase 3 hybrid trial testing three FDA-approved drugs that laboratory evidence suggests may slow biological aging: SGLT2 inhibitors (originally developed for Type 2 diabetes and now widely used in cardiology), rapamycin (an immunosuppressant with well-documented longevity effects in animal models), and semaglutide (the GLP-1 receptor agonist that has reshaped metabolic medicine). Testing these drugs in a single trial against aging biomarkers — rather than disease-specific endpoints — is a fundamentally different paradigm from how any of them were originally studied.

Cambrian BioPharma secured up to $30.8 million to advance a next-generation rapamycin analog into human trials. The rationale: rapamycin itself has robust longevity data in animal models but carries immunosuppressive side effects at the doses used clinically. Cambrian's analog is designed to selectively inhibit mTORC1 — the molecular target responsible for rapamycin's anti-aging effects — while sparing mTORC2, which drives the unwanted immune suppression. If the selectivity holds in humans, it would remove the primary barrier that has kept rapamycin from becoming a mainstream aging intervention.

Linnaeus Therapeutics received up to $22 million for a compound targeting the G protein-coupled estrogen receptor, or GPER. The receptor has established cardiometabolic benefits in preclinical models, and Linnaeus believes activating it can improve multiple aging-related pathways simultaneously. The clinical trial will measure functional and biomarker endpoints in healthy older adults.

Brown University and the University of Rochester are sharing up to $22 million for one of the most conceptually ambitious projects in the program. They are targeting retrotransposons — ancient viral DNA sequences embedded in the human genome that become increasingly active with age, triggering chronic inflammation that accelerates cellular deterioration. The drug being tested, Censavudine (TPN-101), was originally developed to treat HIV by inhibiting reverse transcriptase — the same enzyme retrotransposons use to replicate. The trial will enroll at least 200 healthy adults aged 60-65 across three sites for 48 weeks, measuring changes in mobility, cognition, and vitality.

Biology professors Vera Gorbunova of Rochester and John Sedivy of Brown lead the collaboration, which includes researchers from the Universities of Connecticut, Texas Medical Branch, Texas Health, and Nebraska, along with Transposon Therapeutics, the biotech startup developing TPN-101. As the team frames it: "the goal is not to treat diseases, but to treat aging itself — the normal, healthy process of human aging."

Stanford University is developing a comprehensive "healthspan score" — a composite biomarker dashboard — and validating it through a lifestyle intervention trial using digital health tools. If the score proves sensitive enough to detect intervention effects over short timeframes, it becomes a reusable platform for evaluating future aging treatments.

Columbia University is mining prior clinical trial datasets to identify biomarkers that responded to interventions, working backward from existing human data to find the most promising surrogate endpoints for future healthspan trials.

Apollo Alpha is testing an orally bioavailable compound targeting energy metabolism and inflammation — two of the most consistently implicated pathways in biological aging.

What This Means for Researchers

PROSPR is a signal, not an endpoint. ARPA-H's $144 million is the opening round of what the agency expects to become a sustained investment in aging biology. For researchers in adjacent fields, the implications are concrete.

Biomarker validation is the bottleneck. Every PROSPR team needs reliable, sensitive, reproducible markers of biological aging that can serve as surrogate endpoints in 1-to-3-year trials. The teams building those tools — Stanford's healthspan score, Columbia's retrospective biomarker analysis — are as critical to the program's success as the teams testing drugs. Researchers with expertise in longitudinal cohort data, molecular epidemiology, or functional assessment development are positioned to contribute, either through collaboration with existing PROSPR teams or through future ARPA-H solicitations building on PROSPR's infrastructure.

Repurposed drugs lower the regulatory bar. Three of the seven PROSPR projects are testing drugs that already have FDA approval for other indications. This is not an accident. Using approved drugs with established safety profiles allows trials to focus on efficacy endpoints without the years-long safety evaluation that novel compounds require. Researchers studying the aging effects of existing drug classes — senolytics, NAD+ precursors, metformin — should note that ARPA-H clearly favors approaches that can reach human trials quickly.

Contract-based funding requires a different proposal mentality. ARPA-H contracts are not NIH grants. They require aggressive milestones, defined go/no-go decision points, and willingness to pivot or terminate based on data. Researchers accustomed to the exploratory latitude of R01-style funding need to calibrate their proposals differently: tighter timelines, more specific deliverables, and explicit criteria for what constitutes success or failure at each stage. ARPA-H's open funding opportunities page lists current solicitations, including the Autonomous Interventions and Robotics program with proposals due March 18.

The aging field just became more fundable. For a generation, basic aging researchers struggled to secure NIH funding because the study sections were organized around diseases, not processes. A proposal to study "the biology of aging" competed poorly against a proposal to study "Alzheimer's disease" — even if the underlying mechanism was identical. PROSPR creates a precedent: the federal government is willing to fund aging as a target in its own right, with its own clinical endpoints and its own success criteria. That precedent will influence NIH study section thinking, private foundation grantmaking, and venture capital investment in longevity biotech.

The Bigger Picture

PROSPR sits at the intersection of two tectonic shifts in biomedical research funding. The first is ARPA-H's maturation as a funding agency — moving beyond its initial announcement phase into programs with defined portfolios, milestone contracts, and measurable deliverables. The second is the broader recognition that treating diseases one at a time is biologically and economically inefficient when a single upstream intervention — slowing aging — could delay the onset of all of them simultaneously.

The economic argument is staggering. The United States spends roughly $4.5 trillion annually on healthcare, with the vast majority flowing to conditions that become exponentially more common after age 65. A treatment that extends healthspan by even a few years — delaying the onset of chronic disease rather than treating it after the fact — would reshape not just medicine but the federal budget.

ARPA-H is not waiting for that argument to play out in policy debates. It is running the trials now, with aggressive timelines, measurable milestones, and a willingness to kill projects that do not deliver. For researchers and biotech founders working on longevity, healthspan, or the fundamental biology of aging, the message is clear: the federal government just declared aging a treatable condition and put $144 million on the table to prove it.

Finding the right funding opportunity in a landscape this fast-moving is its own challenge, and Granted can help researchers and biotech teams track ARPA-H solicitations alongside the broader universe of aging and longevity funding that is emerging in response.